Invesco
GYRE icon

Invesco’s Gyre Therapeutics GYRE Stock Holding History

Invesco’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,775
Closed -$67K – 3992
2021
Q1 		$67K Buy
1,775
+181
+11% +$8.27K ﹤0.01% 3809
2020
Q4 		$75K Buy
+1,594
New +$69K ﹤0.01% 3685
2018
Q2 		– Sell
-2,500
Closed -$483K – 3892
2018
Q1 		$483K Buy
+2,500
New +$466K ﹤0.01% 3343
2015
Q2 		– Sell
-4
Closed -$10K – 4350
2015
Q1 		$10K Hold
4
– – ﹤0.01% 3964
2014
Q4 		$9K Hold
4
– – ﹤0.01% 4009
2014
Q3 		$8K Sell
4
-41
-91% -$101K ﹤0.01% 4048
2014
Q2 		$161K Sell
45
-8
-15% -$26.1K ﹤0.01% 3792
2014
Q1 		$199K Sell
53
-6
-10% -$22.2K ﹤0.01% 3747
2013
Q4 		$192K Buy
59
+31
+111% +$122K ﹤0.01% 3809
2013
Q3 		$119K Sell
28
-23
-45% -$92.5K ﹤0.01% 3962
2013
Q2 		$172K Buy
+51
New +$194K ﹤0.01% 3719

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco's GYRE Position: Q2 2021 in Review

Invesco sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 1,775 shares — an estimated $67K sold.

Invesco first reported a position in GYRE in Q2 2013 and held it in 11 quarters. The position peaked at $483K in Q1 2018. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Invesco reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Invesco sold 1,775 Gyre Therapeutics shares in Q2 2021, an estimated $67K.
  • Invesco first reported a position in Gyre Therapeutics in Q2 2013 and held it in 11 quarters.
  • Invesco's Gyre Therapeutics position peaked at $483K in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.